Registrations Open Now!

ADDS 2027

Ametris Digital Data Summit 2027

February 8-10  |  ATLANTA, GA

WATCH RECAP VIDEO
ADDS 2024

ActiGraph Digital Data Summit 2025

February 10-12     |     Pensacola Beach, FL

Connected Lines Pattern

Advancing Digital Measures Towards Scalable Clinical Impact

Join us for the Ametris Digital Data Summit 2027! Now in its fifth year, ADDS is heading to Atlanta once again to facilitate easier access and expanded space and support our growing community. ADDS is a one-of-a-kind scientific conference advancing the adoption of wearable digital health technologies (DHTs) in clinical research by bringing together a multidisciplinary group of digital health leaders for expert-led presentations and collaborative discussions.

AG_Marketing_ADDS_2022_Icons_KeynoteSpeakers_White

Featured Speakers

  • Ametris_ADDS_2027_Speakers_DanaWolff-Huges

    Dana Wolff-Huges, PhD

    Program Officer

    National Cancer Institute

  • Ametris_ADDS_2027_Speakers_RaulTorres

    Raul Torres, PhD

    Associate Director, Data Science

    Takeda

  • Ametris_ADDS_2027_Speakers_DanielLachant

    Daniel Lachant

    Associate Professor of Medicine

    University of Rochester Medical Center

  • Ametris_ADDS_2027_Speakers_JieRen

    Jie Ren, PhD

    Director, Data Science

    Merck

  • Ametris_ADDS_2027_Speakers_PaulHibbing

    Dr. Paul Hibbing, PhD

    Assistant Professor

    University of Illinois Chicago Department of Kinesiology and Nutrition

Check back regularly for new speakers!

Why Attend ADDS 2027

ADDS is your chance to learn from, network with, and develop collaborations with colleagues from a variety of disciplines, including clinicians, data scientists, clinical trialists, digital health technology specialists, and public health researchers.

Scientific Case Studies

Client Case
Studies

Networking Forums

Networking
Forums

Scientific Poster Sessions

Scientific Poster
Session

Panel Discussions

Panel
Discussions

ADDS 2027 Activity

We're excited to add a new activity to the ADDS agenda this year, providing opportunities for deeper discussions, actionable takeaways, and expanded networking within the digital health community.

Pre-Conference Workshop
Parkinson's Disease

Monday, February 8th

Clinical trials of disease-modifying therapies (DMTs) for Parkinson’s disease continue to rely heavily on the MDS-UPDRS Part III as a primary clinical endpoint, despite growing concern that conventional rating scales may lack the sensitivity needed to detect subtle treatment effects—particularly in early-stage populations where intervention may matter most. Against a backdrop of repeated challenges in PD DMT development, this workshop asks a central question for sponsors: are conventional clinical scales alone sufficient to evaluate disease modification?

The session will examine emerging evidence that digitally derived measures (DDMs) can capture PD progression with greater sensitivity than traditional rating scales, drawing on data from longitudinal at-home monitoring and composite measures derived from wearable sensors. Faculty will discuss how continuous measures of walking, non-walking behavior, motor fluctuation, and real-world activity may provide a richer and more responsive view of disease progression than periodic in-clinic assessment alone.

Through expert presentations, interactive roundtables, and moderated debate, participants will explore the scientific, operational, statistical, and regulatory considerations that will determine whether DDMs can be used confidently in PD DMT trials. Discussion will address effect-size and sample-size implications, patient compliance and remote data collection requirements, endpoint interpretability, and the level of evidence needed to support regulatory acceptance or formal qualification.

The workshop will conclude with a practical call to action for sponsors, researchers, regulators, and technology developers: to align on evidence standards, validation pathways, and collaborative studies that can move DDMs from promising exploratory tools to fit-for-purpose endpoints—helping accelerate PD DMT development and increasing the likelihood that trials can detect meaningful treatment effects.

Seats are limited! Please check the box on the ticket form to reserve your seat.

AG_Marketing_ADDS_2022_Icons_StudentPosterContest_WhiteScientific Poster Session

If you have original, unpublished research that involves the use of digital health technologies (DHTs), including wearables, sensors, and/or eCOA, we invite you to submit your abstract for consideration for ADDS 2027 Scientific Poster Session!

SUBMIT YOUR POSTER

What Did Attendees Say About ADDS?

It's nice to have a conference that has a very specific focus, because we can dive much deeper into that and really get into the meat of the data. You can get into a much deeper understanding of the particular topic as well as some of the advancements in the field.

Ariel Dowling, PhD

Head of Sensing and Measurement | Takeda

It's a perfect thing when you can come to a conference, and you can meet people and immediately realize that you have things in common and can help each other; to meet other people who are really in different fields, but experiencing some of the same issues and develop potential collaborations across the board.

Johathan Soslow

Pediatric Cardiologist | Vanderbuilt University

An event like this brings talent that you normally are not exposed to, and as you see these presentations, you're shocked as to how much innovation is out there.

Peter Fernandes

CEO | Bellerophon Therapeutics

I think a lot of us do research in the technology and how we can apply it to our specific research interests or populations, but learning how to cross those boundaries between clinical populations is important.

Jennifer Schrack

Professor of Epidemiology and Medicine | Johns Hopkins Bloomberg School of Public Health

Ariel Dowling
Dr. Jonathan Soslow
Peter Fernandes
Jennifer Schrack, PhD

Thank you to our Premier Sponsor

Signant Health